The pathogenesis of essential thrombocythemia

Current Opinion in Hematology

Volumn 18, Issue 5, 2011, Pages 323-329

  Beer, Philip A ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

clonal heterogeneity; essential thrombocythemia; signaling pathways; transcriptional regulation

Indexed keywords

ADAPTOR PROTEIN; CYTOKINE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; JANUS KINASE 2; LYMPHOCYTE SPECIFIC ADAPTER PROTEIN; PROTEIN; SEX COMBS LIKE 1 PROTEIN; TEN ELEVEN TRANSLOCATION 2 PROTEIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; HEMATOLOGIC MALIGNANCY; HUMAN; MOLECULAR MODEL; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA; TRANSCRIPTION REGULATION;

ANIMALS; DNA-BINDING PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISOCITRATE DEHYDROGENASE; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTORS, THROMBOPOIETIN; REPRESSOR PROTEINS; RISK; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA, ESSENTIAL; TRANSCRIPTION, GENETIC;

EID: 80051786031     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283497f54     Document Type: Review

References (35)

1. Beer PA, Green AR. Pathogenesis and management of essential thrombocythemia. Hematol Am Soc Hematol Educ Program 2009;621-628.
2. Li J, Spensberger D, Ahn JS, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V61 7F-positive essential thrombocythemia. Blood 2010;116:1528-1538. Knock-in mouse model of the human JAK2 V617F mutation recapitulates the phenotype of JAK2-mutant essential thrombocythemia.
3. Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009;461:819-822. The first description of the nuclear localization of JAK2 in hematopoietic cells, and the first study to elucidate the effects of nuclear JAK2 on the regulation of gene transcription, thus changing the JAK2 signaling paradigm.
4. Rinaldi CR, Rinaldi P, Alagia A, et al. Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia. Blood 2010;116:6023-6026.
5. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
6. Ding J, Komatsu H, Iida S, et al. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood 2009;114:3325-3328.
7. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112:141-149.
8. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W> L/K mutation in essential thrombocythemia. Blood 2008;112:844-847.
9. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010;116:988-992. First description of disease-associated mutations in LNK.
10. Pardanani A, Lasho T, Finke C, et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010;24:1713-1718.
11. Bersenev A, Wu C, Balcerek J, et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest 2010;120:2058-2069. Thorough biochemical dissection of the role of LNK in cytokine signaling, setting the scene for the subsequent identification of mutations affecting this protein.
12. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-2301.
13. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839-843. First data on the functional consequences of mutations in TET2, showing an association between mutantTET2 and global DNA hypomethylation (see also [14"]).
14. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553-567. Placed mutations in IDH1 and IDH2 in the same pathway as mutant TET2, but in contrast to the study by Ko et al. [13"], this study demonstrated DNA hypermethylation in patients with TET2 mutations. The discrepancy between these studies is yet to be fully resolved.
15. Wu H, D'Alessio AC, Ito S, et al. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 2011;473:389-393. Identified a complex role for TET1, whose function is thought to be similar to TET2, in both the repression and maintenance of gene expression which is locus and ontogeny dependent.
16. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2010;19:17-30. Placed mutations in IDH1 and IDH2 in the same pathway as mutant TET2.
17. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362:369-370.
18. Cho YS, Kim EJ, Park UH, et al. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem 2006;281:17588-17598.
19. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009;23:2183-2186.
20. Beer PA, Jones AV, Bench AJ, et al. Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol 2009;144:904-908.
21. Beer PA, Delhommeau F, Lecouedic JP, et al. Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010;115:2891-2900. These two studies show by analysis of clonal progenitor colonies that biclonal disease in essential thrombocythemia patients can represent either related progeny of a shared founder clone or the coexistence of two unrelated MPNs in the same patient.
22. Schaub FX, Jager R, Looser R, et al. Clonal analysis of deletions on chromosome 20q and JAK2-V61 7F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V61 7F. Blood 2009;113:2022-2027.
23. Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010;115:2003-2007. These two studies, which used progenitor colonies to assess clonal relationships in MPN patients, highlighted the clonal complexity in these disorders.
24. Olcaydu D, Harutyunyan A, Jager R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009;41:450-454.
25. Jones AV, Campbell PJ, Beer PA, et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 2010;115:4517-4523. First study to show convincingly that the 46/1 haplotype predisposes to MPL-mutant and JAK2/MPL-negative essential thrombocythemia.
26. Beer PA, Ortmann CA, Campbell PJ, Green AR. Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemia. Blood 2010;116:1013-1014.
27. Landgren O, Goldin LR, Kristinsson SY, et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden. Blood 2008;112:2199-2204.
28. Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2 (V617F)-positive myeloproliferative neoplasms. Nat Genet 2009;41:455-459.
29. Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010;149:352-375. Guideline for the diagnosis of essential thrombocythemia from the British Committee for Standards in Haematology, recommending a move away from reliance on bone marrow morphology and towards molecular-based diagnosis.
30. Beer PA, Erber WN, Campbell PJ, Green AR. How I treat essential thrombocythemia. Blood 2010;117:1472-1482.
31. Chen E, Beer PA, Godfrey AL, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010;18:524-535. Study demonstrating that essential thrombocythemia and polycythemia vera can be distinguished by differences in STAT1 signaling, the precise mechanism for which remains unclear.
32. Dahabreh IJ, Zoi K, Giannouli S, et al. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009;33:67-73.
33. Lussana F, Caberlon S, Pagani C, et al. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res 2009;124:409-417.
34. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-911.
35. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-375.